ArticleFrontiers in oncology2026
Pretransplant albumin-to-globulin ratio and long-term outcomes after liver transplantation for hepatocellular carcinoma: a two-center cohort study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prognosis after liver transplantation for hepatocellular carcinoma (HCC) is driven mainly by tumor burden, vascular invasion, and alpha-fetoprotein. Routine pretransplant nutritional indices may add information on recipient condition, but direct comparisons are scarce and recurrence is not always analyzed with competing mortality. Methods: The development cohort included 254 adults undergoing first liver transplantation for pathologically confirmed HCC. Overall survival (OS) was the primary outcome; time to recurrence (TTR) was analyzed with death before recurrence as a competing event. Five nutritional indices were compared using Kaplan-Meier estimates, Cox regression, and restricted cubic splines. AGR underwent subgroup and Fine-Gray analyses. Conventional staging, AGR alone, a pretransplant clinical model, and the clinical model plus AGR were compared by discrimination, calibration, and decision curves. Time-dependent ROC curves included bootstrap 95% confidence intervals. Fixed development-model parameters were evaluated in an independent external validation cohort of 58 recipients. Results: Eighty-five patients died and 51 experienced recurrence. In the fully adjusted Cox model, each 1-standard-deviation (SD) increase in AGR was associated with lower overall mortality [hazard ratio (HR), 0.64; 95% confidence interval (CI), 0.48-0.84; P = 0.002]; GNRI was also associated with OS (HR, 0.75; 95% CI, 0.58-0.98; P = 0.037). The AGR-OS association was nonlinear (overall P < 0.001; nonlinear P = 0.004). The adjusted recurrence subdistribution HR was 0.66 per 1-SD increase in AGR (95% CI, 0.47-0.94; P = 0.022). Adding AGR increased the OS C-index from 0.750 to 0.780 in the development cohort and from 0.645 to 0.686 externally. At 3 years, the external AUC was 0.713 (95% CI, 0.574-0.834) for the clinical model and 0.764 (95% CI, 0.614-0.888) after AGR was added. Conclusions: AGR showed the most consistent associations with OS and recurrence among the five indices. Its addition produced modest improvements in the development cohort, with changes in the same direction during external validation. AGR may complement, but should not replace, established tumor-related prognostic factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.